ROS1 and non-small cell lung carcinoma: In addition, Dziadziuszko et al. investigated the clinical validity of an FDA approved pan-tumor liquid biopsy assay using ctDNA in identifying patients with fusion positive ROS1 NSCLC receiving entrectinib and subsequently assessed the pre- and post-treatment genomic landscape of these patients [67].